Telmisartan amideCAS# 915124-86-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 915124-86-6 | SDF | Download SDF |
PubChem ID | 11978018 | Appearance | Powder |
Formula | C33H31N5O | M.Wt | 513.6 |
Type of Compound | Impurities | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2-[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl]phenyl]benzamide | ||
SMILES | CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)N)C=C(C=C2C)C5=NC6=CC=CC=C6N5C | ||
Standard InChIKey | YAIWQMXHIQDCFT-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C33H31N5O/c1-4-9-30-36-31-21(2)18-24(33-35-27-12-7-8-13-28(27)37(33)3)19-29(31)38(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)32(34)39/h5-8,10-19H,4,9,20H2,1-3H3,(H2,34,39) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Telmisartan amide Dilution Calculator
Telmisartan amide Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.947 mL | 9.7352 mL | 19.4704 mL | 38.9408 mL | 48.676 mL |
5 mM | 0.3894 mL | 1.947 mL | 3.8941 mL | 7.7882 mL | 9.7352 mL |
10 mM | 0.1947 mL | 0.9735 mL | 1.947 mL | 3.8941 mL | 4.8676 mL |
50 mM | 0.0389 mL | 0.1947 mL | 0.3894 mL | 0.7788 mL | 0.9735 mL |
100 mM | 0.0195 mL | 0.0974 mL | 0.1947 mL | 0.3894 mL | 0.4868 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2-(2-Aminopropan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide
Catalog No.:BCN9633
CAS No.:518048-03-8
- Benzyl(2-(4-((4-fluorobenzyl)carbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl)carbamate
Catalog No.:BCN9632
CAS No.:518048-02-7
- 1-(2-Chloroacetyl)pyrrolidine-2-carbonitrile
Catalog No.:BCN9631
CAS No.:207557-30-5
- Tricin 7-O-glucoside
Catalog No.:BCN9630
CAS No.:32769-01-0
- Pedaliin
Catalog No.:BCN9629
CAS No.:22860-72-6
- Lutonarin
Catalog No.:BCN9628
CAS No.:35450-86-3
- (S)-4-Methoxydalbergione
Catalog No.:BCN9627
CAS No.:2543-95-5
- Neochlorogenin
Catalog No.:BCN9626
CAS No.:511-91-1
- Dihydrodehydrodiconiferyl Alcohol Beta-D-Xylopyranoside
Catalog No.:BCN9625
CAS No.:1048996-18-4
- Umtatin
Catalog No.:BCN9624
CAS No.:17398-06-0
- 16-Oxo-21-episerratenediol
Catalog No.:BCN9623
CAS No.:1194739-51-9
- O-Methylalloptaeroxylin
Catalog No.:BCN9622
CAS No.:35930-31-5
- Telmisartan impurity G
Catalog No.:BCN9635
CAS No.:144702-27-2
- cis-1,2,3,4-Tetrahydro-1-(3,4-methylenedioxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxylic acid methyl ester hydrochloride
Catalog No.:BCN9636
CAS No.:171752-68-4
- Methyl 1-(benzo[d][1,3]dioxol-5-yl)-2-(2-chloroacetyl)-2,3,4,9-tetra-hydro-1H-pyrido[3,4-b]indole-3-carboxylate
Catalog No.:BCN9637
CAS No.:171489-59-1
- Norgestrel
Catalog No.:BCN9638
CAS No.:6533-00-2
- Diethyl 2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioate 4-methylbenzenesulfonate
Catalog No.:BCN9639
CAS No.:165049-28-5
- 2-Iodo-3-oxo-4-azaandrostane-17-carboxylic acid
Catalog No.:BCN9640
CAS No.:104239-97-6
- 6-Des(1-methyl-2-benzimidazolyl)-6-carboxy telmisartan
Catalog No.:BCN9641
CAS No.:884330-12-5
- 3-[[[2-[[(4-Cyanophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]pyridin-2-ylamino]propionic acid ethyl ester
Catalog No.:BCN9642
CAS No.:211915-84-3
- Toluene-4-sulfonic acid 5-(2,4-difluorophenyl)-5-(1H-1,2,4-triazol-1-yl)methyltetrahydrofuran-3-ylmethyl ester
Catalog No.:BCN9643
CAS No.:149809-43-8
- 2-[(1S,2S)-1-Ethyl-2-bezyloxypropyl]-2,4-dihydro-4-[4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-3H-1,2,4-triazol-3-one
Catalog No.:BCN9644
CAS No.:184177-83-1
- Teriflunomide
Catalog No.:BCN9645
CAS No.:163451-81-8
- 5-[2-[[(4-Methoxyphenyl)diphenylmethyl]amino]-6-(phenylmethoxy)-9H-purin-9-yl]-3-(phenylmethoxy)-2-[(phenylmethoxy)methyl]cyclopentanol
Catalog No.:BCN9646
CAS No.:142217-78-5
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARgamma activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.[Pubmed:32272420]
Eur J Med Chem. 2020 Jun 1;195:112258.
4'-((2-Propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid derived from telmisartan was identified as lead for the design of cell death modulators. In this study, we evaluated the efficacy of telmisartan itself and other sartans in combination with imatinib against K562-resistant cells. The findings were directly used to further optimize the lead structure. Telmisartan and candesartan cilexetil represented the most effective sartans, thus the influence of carboxyl/methyl carboxylate groups at positions 7 (compounds 6, 7) or 4 (compounds 12-14) at the benzimidazole core was studied. Additionally, according to the results of a former structure-activity study, telmisartan was transformed to the related amide (1). Telmisartan amide 1, as well as the esters 6 and 12 markedly sensitized the resistant CML cells to imatinib treatment. Correlation with their potency to activate PPARgamma is not given. Candesartan cilexetil, telmisartan and 1 showed the profile of partial agonists at PPARgamma with EC50 values of 4.2, 4.3 and 9.1 muM, respectively, while 6 and 12 caused only marginal intrinsic activation at 10 muM (Amax = 22% and 13%). However, the repression of the STAT5 phosphorylation relates with the possibility to sensitize K562-resistant CML cells to imatinib treatment. It is worth mentioning that all compounds were per se non-cytotoxic at relevant concentrations.